Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UCB, Inc.
ClinicalTrials.gov Identifier:
NCT00490035
First received: June 21, 2007
Last updated: February 19, 2013
Last verified: February 2013
  Purpose

This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.


Condition Intervention Phase
Epilepsy
Other: Placebo
Drug: Brivaracetam
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.

Resource links provided by NLM:


Further study details as provided by UCB, Inc.:

Primary Outcome Measures:
  • Partial onset seizure (Type I) frequency per week over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Partial onset seizure (Type I) frequency per week over the 12-week Treatment Period


Secondary Outcome Measures:
  • Responder rate for partial onset seizures (Type I) frequency per week over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Responder rate for partial onset seizures (Type I) frequency per week over the 12-week Treatment Period

  • All seizure frequency (Type I+II+III) per week over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    All seizure frequency (Type I+II+III) per week over the 12-week Treatment Period

  • Percent change from Baseline to the 12-week Treatment Period in partial onset seizure (Type I) frequency per week [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Percent change from Baseline to the 12-week Treatment Period in partial onset seizure (Type I) frequency per week

  • Categorized percentage change from Baseline in seizure frequency for partial onset seizure (Type I)over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Categorized percentage change from Baseline in seizure frequency for partial onset seizure (Type I) over the 12-week Treatment Period

  • Seizure freedom rate (all seizure types) over the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Seizure freedom rate (all seizure types) over the 12-week Treatment Period

  • Time to first Type I seizure during the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Time to first Type I seizure during the 12-week Treatment Period

  • Time to fifth Type I seizure during the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Time to fifth Type I seizure during the 12-week Treatment Period

  • Time to tenth Type I seizure during the 12-week Treatment Period [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Time to tenth Type I seizure during the 12-week Treatment Period

  • Reduction of Type IC/Type I seizure frequency ratio from Baseline to the 12- week Treatment Period. [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Reduction of Type IC/Type I seizure frequency ratio from Baseline to the 12- week Treatment Period.

  • Change from Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score

  • Change from Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score

  • Change from Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) score

  • Change from Baseline to the 12-week Treatment Period in Hospital Anxiety score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Hospital Anxiety score

  • Change from Baseline to the 12-week Treatment Period in Hospital Depression score [ Time Frame: Baseline to 12-week Treatment Period ] [ Designated as safety issue: No ]
    Change from Baseline to the 12-week Treatment Period in Hospital Depression score

  • Patient's Global Evaluation Scale (P-GES) evaluated at last visit or early discontinuation visit [ Time Frame: Baseline to last visit or early discontinuation visit in the 12-week Treatment Period ] [ Designated as safety issue: No ]
    Patient's Global Evaluation Scale (P-GES) evaluated at last visit or early discontinuation visit

  • Investigator's Global Evaluation Scale (I-GES) evaluated at last visit or early discontinuation visit [ Time Frame: Baseline to last visit or early discontinuation visit in the 12-week Treatment Period ] [ Designated as safety issue: No ]
    Investigator's Global Evaluation Scale (I-GES) evaluated at last visit or early discontinuation visit


Enrollment: 398
Study Start Date: September 2007
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Matching Placebo tablets administered twice a day
Other: Placebo
Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
Experimental: Brivaracetam 20 mg/day
Brivaracetam 20 mg/day, 10 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
Experimental: Brivaracetam 50 mg/day
Brivaracetam 50 mg/day, 25 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
Experimental: Brivaracetam 100 mg/day
Brivaracetam 100 mg/day, 50 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.

  Eligibility

Ages Eligible for Study:   16 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects were from 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
  • Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
  • Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)
  • Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1
  • Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period
  • Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant AED

Exclusion Criteria:

  • History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3
  • History or presence of status epilepticus during the year preceding Visit 1 or during Baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00490035

  Hide Study Locations
Locations
Belgium
13
Gent, Belgium
19
La Louviere, Belgium
12
Liege, Belgium
10
Saint-Vith, Belgium
Finland
44
Kuopio, Finland
41
Oulu, Finland
42
Seinajoki, Finland
43
Tampere, Finland
France
60
Angers Cedex 9, France
56
Bethune, France
62
Bron, France
57
Dijon, France
53
Lille, France
52
Montpellier Cedex, France
64
Nancy, France
54
Paris, France
51
Rennes, France
61
Roanne, France
55
Strasbourg, France
Germany
76
Bad Berka, Germany
73
Berlin, Germany
79
Bernau, Germany
78
Bielefeld, Germany
74
Freiburg, Germany
75
Kehl-Kork, Germany
77
Mainz, Germany
70
Munchen, Germany
72
Radeberg, Germany
71
Ulm, Germany
Hungary
94
Budapest, Hungary
90
Debrecen, Hungary
92
Pecs, Hungary
India
256
Bangalore, India
257
Bangalore, India
253
Hyderabad, India
258
Jaipur, India
255
Kolkata, India
250
Lucknow, India
259
Mumbai, India
270
Pune, India
251
Pune Maharashtra, India
Italy
104
Bologna, Italy
105
Foggia, Italy
101
Perugia, Italy
103
Roma, Italy
107
Roma, Italy
Netherlands
124
Breda, Netherlands
125
Den Haag, Netherlands
122
Zwolle, Netherlands
Poland
142
Bialystok, Poland
143
Gdansk, Poland
153
Grodzisk Mazowiecki, Poland
151
Katowice, Poland
147
Katowice, Poland
141
Kielce, Poland
150
Krakow, Poland
148
Lodz, Poland
144
Lublin, Poland
152
Poznan, Poland
146
Szczecin, Poland
145
Warsaw, Poland
149
Warszawa, Poland
140
Warszawa, Poland
Spain
187
Alcorcon, Spain
181
Barcelona, Spain
182
Madrid, Spain
184
San Sebastian, Spain
183
Vigo, Spain
185
Zaragoza, Spain
Switzerland
201
Biel, Switzerland
205
Geneve, Switzerland
203
St Gallen, Switzerland
202
Tschugg, Switzerland
204
Zürich, Switzerland
United Kingdom
223
Liverpool, United Kingdom
224
Middlesborough, United Kingdom
Sponsors and Collaborators
UCB, Inc.
Investigators
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
  More Information

No publications provided by UCB, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: UCB, Inc.
ClinicalTrials.gov Identifier: NCT00490035     History of Changes
Other Study ID Numbers: N01252, 2006-006344-59
Study First Received: June 21, 2007
Last Updated: February 19, 2013
Health Authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Netherlands: Medicines Evaluation Board (MEB)
Poland: Ministry of Health
Switzerland: Swissmedic
Hungary: National Institute of Pharmacy
India: Drugs Controller General of India

Keywords provided by UCB, Inc.:
Epilepsy
Brivaracetam
Partial Onset Seizures

Additional relevant MeSH terms:
Epilepsy
Seizures
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on July 24, 2014